JNJ vs MOH: fair value comparison
Johnson & Johnson and Molina Healthcare, Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, JNJ currently sits closer to the top of our discount ranking.
| JNJ | MOH | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $275.23 | $200.80 |
| 12-month range | $185.08–$271.19 | $135.82–$203.06 |
| Sector rank | #110 of 113 Healthcare | #112 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: JNJ fair value analysis · MOH fair value analysis